Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
1 finding from 1 review
Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · psychosis‐induced aggression or agitation
1 finding from 1 review
Cost‐effectiveness · psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
Benzodiazepines showed no clear difference in tranquillisation or asleep: sedation ‐ medium term vs haloperidol… compared with antipsychotics (low certainty).
1 finding from 1 review
Global state: no improvement ‐ vs haloperidol ‐ medium term As defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines showed no clear difference in global state: no improvement ‐ vs haloperidol ‐ medium term As… compared with antipsychotics (low certainty).
1 finding from 1 review
Global state: no improvement ‐ vs olanzapine ‐ medium term As defined in each study · psychosis‐induced aggression or agitation
It is very uncertain whether benzodiazepines changes global state: no improvement ‐ vs olanzapine ‐ medium term As… compared with antipsychotics (very low certainty).
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · psychosis‐induced aggression or agitation
HALOPERIDOL may leads to higher adverse effects compared with OTHER ANTIPSYCHOTICS: g. QUETIAPINE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state: PANSS responders (ITT data) ‐ medium term PANSS responders‐ participants achieving a >30% improvement in total score · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in mental state: PANSS responders (ITT data) ‐ medium term PANSS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Adverse events: Movement disorder requiring the use of anti‐EPS medication ‐ medium term · patients with schizophrenia
RISPERIDONE DEPOT probably leads to higher adverse events: Movement disorder requiring the use of anti‐EPS… compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (moderate certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review